U.S. markets closed

Swedish Orphan Biovitrum AB (publ) (SOBI.ST)

Stockholm - Stockholm Real Time Price. Currency in SEK
231.60+1.60 (+0.70%)
At close: 05:29PM CET
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close230.00
Bid231.20 x 0
Ask231.30 x 0
Day's Range229.10 - 232.70
52 Week Range177.45 - 245.50
Avg. Volume372,454
Market Cap68.552B
Beta (5Y Monthly)0.37
PE Ratio (TTM)22.55
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for SOBI.ST

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Reuters

      UPDATE 2-U.S. authorizes Sobi's drug to treat COVID-19 in high-risk patients

      Sobi North America, a unit of Swedish Orphan Biovitrum AB, said on Thursday the U.S. Food and Drug Administration authorized its arthritis drug for treatment of high-risk hospitalized COVID-19 patients. The drug, already approved in the European Union for treating COVID, has been authorized in the United States to treat patients with pneumonia who require oxygen support and those at risk of developing severe respiratory failure. The authorization of Sobi's Kineret adds another option for COVID treatment in the United States, as the disease moves from a pandemic to an endemic stage.

    • Zacks

      Swedish Orphan Biovitrum (BIOVF) Beats Q3 Earnings Estimates

      Swedish Orphan Biovitrum (BIOVF) delivered earnings and revenue surprises of 16.67% and 2.26%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

    • Zacks

      Are Medical Stocks Lagging Alimera Sciences (ALIM) This Year?

      Here is how Alimera Sciences (ALIM) and Swedish Orphan Biovitrum (BIOVF) have performed compared to their sector so far this year.